Physician profile
John Hwang
NPI 1457349177
$48,433.77
in general payments reported to CMS, 2019-2025
81 companies · $8,185 in 2025
The $8,185 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,676 · 2020: $2,241 · 2021: $4,446 · 2022: $11K · 2023: $11K · 2024: $9,213 · 2025: $8,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $11K · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,875.00 |
| Food and Beverage | $11,326.21 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $27,400.27 | 2019-2025 | |
| Novo Nordisk INC | $4,424.11 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $2,727.77 | 2019-2025 | Otezla, Repatha, Evenity |
| Biohaven Pharmaceuticals, INC. | $1,288.43 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,081.94 | 2019-2025 | Jardiance, Tradjenta |
| Lilly USA, LLC | $974.56 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $673.65 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Incyte Corporation | $662.86 | 2024-2025 | Opzelura, Opzelura |
| Glaxosmithkline, LLC. | $620.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boston Scientific Corporation | $618.83 | 2019-2025 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $577.09 | 2021-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $522.11 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $443.50 | 2020-2025 | Trintellix, Entyvio, Eohilia |
| Merck Sharp & Dohme LLC | $417.47 | 2019-2025 | Steglatro, Belsomra, Capvaxive |
| Axsome Therapeutics, INC. | $361.39 | 2022-2025 | Sunosi, Auvelity |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.